Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Feasibility of Permacol Use in Infected Fields

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00820040
Recruitment Status : Terminated (Slow enrollment due to strict eligibility criteria)
First Posted : January 9, 2009
Results First Posted : December 9, 2020
Last Update Posted : December 9, 2020
Sponsor:
Information provided by (Responsible Party):
Medtronic - MITG

Brief Summary:
This pilot study is to examine the feasibility of using Permacol Surgical Implant in the repair of abdominal wall defects after removal of infected prosthetic mesh

Condition or disease Intervention/treatment Phase
Hernia Device: acellular porcine dermal collagen mesh Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: To Examine the Feasibility of Using Permacol® Surgical Implant in the Repair of Abdominal Wall Defects After Removal of Chronic Infect Prosthetic Mesh
Study Start Date : July 2009
Actual Primary Completion Date : August 2011
Actual Study Completion Date : August 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hernia

Arm Intervention/treatment
Experimental: Permacol Device: acellular porcine dermal collagen mesh
porcine mesh for hernia repair/ abdominal wall reconstruction
Other Name: Permacol




Primary Outcome Measures :
  1. Number of Participants With Hernia Recurrence or Surgical Site Infection Requiring Wound Opening [ Time Frame: 12 months ]
    The primary objective of this study was hernia recurrence or surgical site infection as assessed by a CT scan 12 months following surgery.Hernia recurrence was defined as any abnormal abdominal protrusion, as assessed by 12 month CT. Surgical site infection requiring wound opening was defined as abscess formation or drainage that required surgical wound opening. Wound opening was defined as surgical entry into the wound.


Secondary Outcome Measures :
  1. Subjects Having Permacol Implants Removed or Debrided After Implantation [ Time Frame: 12 months ]
    The secondary objective of this study was the incidence of Permacol™ surgical implant removal or debridement. Removal was defined as complete surgical excision of the implant. Debridement was defined as debridement or lavage of ≥10% of the visible implant surface area as subjectively assessed by the operating surgeon.


Other Outcome Measures:
  1. Physical and Other Examinations [ Time Frame: 12-month post-procedure change from baseline ]
    The SF-12v2 Health Survey® (12-question short form health survey) measure eight domains of health related quality of life, which is then aggregated to provide summary measure of the respondent's physical and mental health. Results of 12-month abdominal CT examination are summarized as a change from the baseline. The SF-12v2 Health Survey® is broken into physical health and mental health. Physical health is determined by: physical functioning, role-playing, bodily pain and general health. Mental health is determined by: vitality, social functioning, role-emotional and mental health. The general population mean of the United States is 50. When analyzing the results, the mean values of the study subjects are taken and compared to the general United States population. Each 10 points represent one standard deviation. A measure of one standard deviation (10 points) below the population mean (50) indicates significant function impairment.

  2. Physical and Other Examinations [ Time Frame: Baseline ]
    The SF-12v2 Health Survey® (12-question short form health survey) measure eight domains of health related quality of life, which is then aggregated to provide summary measure of the respondent's physical and mental health. Results of 12-month abdominal CT examination are summarized as a change from the baseline. The SF-12v2 Health Survey® is broken into physical health and mental health. Physical health is determined by: physical functioning, role-playing, bodily pain and general health. Mental health is determined by: vitality, social functioning, role-emotional and mental health. The general population mean of the United States is 50. When analyzing the results, the mean values of the study subjects are taken and compared to the general United States population. Each 10 points represent one standard deviation. A measure of one standard deviation (10 points) below the population mean (50) indicates significant function impairment.

  3. Physical and Other Examinations [ Time Frame: 12-month post-procedure ]
    The SF-12v2 Health Survey® (12-question short form health survey) measure eight domains of health related quality of life, which is then aggregated to provide summary measure of the respondent's physical and mental health. Results of 12-month abdominal CT examination are summarized as a change from the baseline. The SF-12v2 Health Survey® is broken into physical health and mental health. Physical health is determined by: physical functioning, role-playing, bodily pain and general health. Mental health is determined by: vitality, social functioning, role-emotional and mental health. The general population mean of the United States is 50. When analyzing the results, the mean values of the study subjects are taken and compared to the general United States population. Each 10 points represent one standard deviation. A measure of one standard deviation (10 points) below the population mean (50) indicates significant function impairment.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Have given written Informed Consent
  • Be 18-85 years of age (inclusive)
  • Have prosthetic mesh that is in proximity to an infected wound that has failed conservative management for at least 3 months, with mesh exposure and a draining wound, or that is in proximity to an abscess that requires operative intervention.
  • Have a wound characterized by purulent discharge, positive gram stain or positive culture to document infection
  • Be a candidate for surgical removal of infected mesh placed for repair of ventral/incisional hernias and concomitant abdominal wall reconstruction
  • Have an ASA Score ≤3
  • Have a body mass index (BMI) between 16.5 and 40 inclusive
  • Be a candidate for anticipated primary approximation of skin/wound
  • Have a life expectancy of at least 18 months
  • Be willing to allow biopsy of implant if secondary wound opening is performed or spontaneous implant exposure occurs

Exclusion Criteria:

  • Have loss of abdominal domain such that the operation would be impractical or would adversely effect respiratory or cardiovascular function to an unacceptable degree
  • Have an enterocutaneous fistula in proximity to wound/mesh
  • Be a candidate for emergency surgery that would make giving valid Informed Consent impractical
  • Be currently taking part in another clinical study that conflicts with the current study
  • Have known allergy to porcine collagen products
  • Have active generalized peritonitis or intraperitoneal sepsis
  • Have active necrotizing fasciitis
  • Have active abdominal compartment syndrome
  • Have active untreated metabolic or systemic illness
  • Report unintentional weight loss >10% of body weight in the previous 90 days
  • Have known collagen metabolism disorder.(e.g., Ehlers-Danlos syndrome)
  • Have known altered immune response (e.g., HIV or other immunodeficiency disorder))
  • Have chronic renal failure
  • Have known active malignancy present
  • Have history of systemic chemotherapy within previous 1 year
  • Have lifetime history of radiation to the abdomen, pelvis or thorax
  • Have inguinal or groin hernia as primary diagnosis
  • Be currently pregnant or planning to become pregnant during study period
  • Be unable to give valid informed consent or comply with required follow- up schedule
  • Suffer from mental capacity sufficiently severe to make informed consent unobtainable

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00820040


Locations
Layout table for location information
United States, Kentucky
University of Kentucky
Lexington, Kentucky, United States, 40536
United States, New York
Albany Medical College
Albany, New York, United States, 12208
United States, South Carolina
Greenville Hospital System
Greenville, South Carolina, United States, 29605
Sponsors and Collaborators
Medtronic - MITG
Investigators
Layout table for investigator information
Principal Investigator: John Roth, MD University of Kentucky
Layout table for additonal information
Responsible Party: Medtronic - MITG
ClinicalTrials.gov Identifier: NCT00820040    
Other Study ID Numbers: Hern06R2
First Posted: January 9, 2009    Key Record Dates
Results First Posted: December 9, 2020
Last Update Posted: December 9, 2020
Last Verified: November 2020
Keywords provided by Medtronic - MITG:
Hernia
Contaminated Field
Mesh Removal
infected mesh removal
Additional relevant MeSH terms:
Layout table for MeSH terms
Hernia
Pathological Conditions, Anatomical